Susquehanna International Group
RNAC icon

Susquehanna International Group’s Cartesian Therapeutics RNAC Stock Holding History

Susquehanna International Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,330
Closed -$99.7K – 13415
2025
Q3 		$126K Buy
12,330
+760
+7% +$8.54K ﹤0.01% 11413
2025
Q2 		$120K Sell
11,570
-890
-7% -$9.48K ﹤0.01% 11673
2025
Q1 		$164K Buy
+12,460
New +$223K ﹤0.01% 11136
2024
Q2 		– Sell
-1,505
Closed -$29.3K – 13049
2024
Q1 		$29.3K Sell
1,505
-3,863
-72% -$81.9K ﹤0.01% 11727
2023
Q4 		$111K Buy
+5,368
New +$160K ﹤0.01% 11240
2023
Q3 		– Sell
-1,198
Closed -$40.2K – 12823
2023
Q2 		$40.2K Sell
1,198
-26,838
-96% -$961K ﹤0.01% 11419
2023
Q1 		$1.17M Buy
28,036
+27,347
+3,969% +$1.29M ﹤0.01% 6406
2022
Q4 		$23.4K Sell
689
-571
-45% -$24.3K ﹤0.01% 11706
2022
Q3 		$61K Sell
1,260
-3,294
-72% -$181K ﹤0.01% 12082
2022
Q2 		$179K Buy
4,554
+3,305
+265% +$98K ﹤0.01% 10804
2022
Q1 		$46K Sell
1,249
-3,642
-74% -$228K ﹤0.01% 12345
2021
Q4 		$478K Sell
4,891
-472
-9% -$50.8K ﹤0.01% 9331
2021
Q3 		$669K Buy
5,363
+4,020
+299% +$485K ﹤0.01% 8634
2021
Q2 		$168K Buy
+1,343
New +$160K ﹤0.01% 11767
2021
Q1 		– Sell
-547
Closed -$67.9K – 12757
2020
Q4 		$50K Buy
547
+152
+38% +$13.2K ﹤0.01% 10753
2020
Q3 		$29K Buy
+395
New +$30.3K ﹤0.01% 10336
2020
Q2 		– Sell
-9,621
Closed -$872K – 10791
2020
Q1 		$696K Buy
+9,621
New +$929K ﹤0.01% 6208
2019
Q1 		– Sell
-423
Closed -$34K – 9687
2018
Q4 		$34K Sell
423
-1,508
-78% -$344K ﹤0.01% 8586
2018
Q3 		$901K Buy
+1,931
New +$776K ﹤0.01% 5429
2018
Q2 		– Sell
-672
Closed -$205K – 10271
2018
Q1 		$205K Buy
+672
New +$191K ﹤0.01% 8285
2017
Q2 		– Sell
-447
Closed -$192K – 9716
2017
Q1 		$192K Buy
+447
New +$188K ﹤0.01% 8034

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's RNAC Position: Q4 2025 in Review

Susquehanna International Group sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 12,330 shares — an estimated $99.7K sold.

Susquehanna International Group first reported a position in RNAC in Q1 2017 and held it in 21 quarters. The position peaked at $1.17M in Q1 2023. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Susquehanna International Group reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 12,330 Cartesian Therapeutics shares in Q4 2025, an estimated $99.7K.
  • Susquehanna International Group first reported a position in Cartesian Therapeutics in Q1 2017 and held it in 21 quarters.
  • Susquehanna International Group's Cartesian Therapeutics position peaked at $1.17M in Q1 2023.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.